News for Arcus Biosciences, Inc. (RCUS)

Deep dive into Arcus Biosciences Inc's financial health and strategic positioning.Comprehensive SWOT analysis to inform investment decisions.Expert evaluation

Summary Arcus Biosciences Inc (RCUS), a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies, has announced its particip

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 11.97% and 9.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $36 million for Q4 2024, surpassing the estimated $28.90 million.Earnings Per Share (EPS): Reported at -$1.03, better than the estimated -$1.32.Net Lo

Arcus Biosciences Inc (RCUS), a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ending December 3

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences Inc (RCUS), a clinical-stage global biopharmaceutical company, announced on February 21, 2025, that its Compensation Committee has granted equ

Arcus Biosciences Inc (RCUS) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 revenue is $28.90 million, and the earni

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

On February 18, 2025, Gilead Sciences, Inc. executed a significant stock transaction involving Arcus Biosciences Inc (RCUS). The firm added 9,630,525 shares of

Summary Arcus Biosciences Inc (RCUS), a clinical-stage biopharmaceutical company, announced the expiration of Gilead's exclusive option rights to casdatifan, a

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.

Arcus Biosciences Inc (RCUS), a clinical-stage biopharmaceutical company, presented new data on its HIF-2a inhibitor, casdatifan, at the 2025 American Society o

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Significant Transaction by Ikarian Capital, LLC (Trades, Portfolio) On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) executed a noteworthy transac

Significant Transaction by Ikarian Capital, LLC (Trades, Portfolio) On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) executed a noteworthy transac

Significant Transaction by Ikarian Capital, LLC (Trades, Portfolio) On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) executed a noteworthy transac

Significant Transaction by Ikarian Capital, LLC (Trades, Portfolio) On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) executed a noteworthy transac

Overview of the Recent Transaction On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a strategic move by acquiring 967,867 shares of Alpha Cog